From:
(CAB-KYRIAKIDES)
Sent:
mercredi 1 juillet 2020 11:14
To:
(CAB-KYRIAKIDES);
(CAB-
KYRIAKIDES);
(CAB-KYRIAKIDES);
(CAB-KYRIAKIDES)
Cc:
(CAB-KYRIAKIDES)
Subject:
Report from meeting with Endocrine Society (cancer,
chemicals)
Attachments:
BTO ED society 30062020.doc
FYI
EUROPEAN COMMISSION
HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL
Brussels, 30 June 2020
MEETING WITH THE ENDOCRINE SOCIETY EDC ADVISORY GROUP
COUNTERPART
SANTE
Commissioner Kyriakidis,
ueller, (CAB-
Kyriakides)
(DG SANTE E2)
WHERE, WHEN Via videoconference, Tuesday 20 June 2020
SUBJECT
Endocrine Disruptors (EDs)
OBJECTIVE OF On request of the Endocrine Society as regards their position on the science of EDs
THE MEETING
and their regulation in the EU
RESULT
The Group presented themselves and the context in which they requested the meeting.
In general they have been encouraged by the commitment given from Commissioner
Kyriakidis on EDs and wish to offer their scientific expertise. They have already
submitted comments to the Commission’s ED Fitness Check exercise and to the
Chemicals Strategy roadmap.
They presented a Powerpoint (see annex) putting forward their concerns on exposures
to EDs and health effects, gaps in EU regulation and the need for immediate action to
protect consumers. In particular they promoted inclusion of EDs in the EU Cancer Plan
given links with prostate and breast cancers; the need to harmonise more sectors
beyond pesticides and biocides including addressing food contact materials (FCMs)
and cosmetic; and the links with increased vulnerability of immune-deficient
individuals and other illnesses that may be linked with EDs during times of pandemic
such as COVID-19.
They emphasised the important aspects they consider on EDs such as low-dose, non-
monotonic effects and cumulative exposures. The impact on vulnerable populations
including children, babies and pregnant women was also highlighted as were the roles
that EDs can play in diseases such as cancer, growth issues, neurodevelopmental
issues, diabetes and metabolic diseases, where they consider presence of EDs
exacerbate the effects of diet, including for example sugar.
They presented a table included in the report on EDs commissioned by the
Parliament’s PETI committee for which Barbara Demeneix was an author, giving an
overview of where they consider gaps in the current EU regulatory framework. They
consider that classification in the CLP Regulation and thus identification would make
it easier to regulate EDs in downstream legislation such as cosmetics and FCMs where
they consider their presence unjustified. They consider EU action even more important
in the global context, where third countries follow the EU approach.
Commissioner Kyriakidis thanked the participants and that the Commission shares
their ambitions for a horizontal and harmonised approach, which will be addressed
under the Chemicals Strategy. In this respect, the Society was encouraged to also put
across its views to Commissioners Sinkeviþius and Breton, who also have
responsibility for this issue. Commissioner Kyriakidis agreed that EDs should be
considered in the Cancer Plan and referred to the substantial additional budget set aside
for the EU4Health initiative, which also focuses on non-communicable diseases.
FOLLOW-UP
Endocrine Society will aim to speak with Commissioner Breton (having already met
Sinkeviþius) and were asked to send any more relevant information as soon as
possible.
Annex
Endocrine Society presentation
+HDOWK&RPPLVVLR
6OLG
),1$/
2
Document Outline